| Literature DB >> 32441298 |
Julia K Bosdou1, Panagiotis Anagnostis2, Dimitrios G Goulis2, Georgios T Lainas1, Basil C Tarlatzis1, Grigoris F Grimbizis1, Efstratios M Kolibianakis1.
Abstract
BACKGROUND: Women who achieve pregnancy by ART show an increased risk of obstetric and perinatal complications compared with those with spontaneous conception (SC). OBJECTIVE AND RATIONALE: The purpose of this systematic review and meta-analysis was to synthesize the best available evidence regarding the association between ART and gestational diabetes mellitus (GDM) in women with singleton pregnancies. The research question asked was whether the risk of GDM is higher in women achieving singleton pregnancy by ART compared with those achieving singleton pregnancy spontaneously. SEARCHEntities:
Keywords: ART; IVF/ICSI; embryo transfer; gestational diabetes mellitus; singleton pregnancy; spontaneous conception
Mesh:
Year: 2020 PMID: 32441298 PMCID: PMC7317285 DOI: 10.1093/humupd/dmaa011
Source DB: PubMed Journal: Hum Reprod Update ISSN: 1355-4786 Impact factor: 15.610
Figure 1Flow diagram for selection of studies on risk of gestational diabetes mellitus after spontaneous and ART pregnancies.
Characteristics of the 38 eligible studies included in the systematic review.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Retrospective cross-sectional/September 2011–October 2012 | 95/215 | No | Women with singleton pregnancies conceived following ART or spontaneously/PCOS, age > 40 years, family history of diabetes in first-degree relatives, pre-pregnancy diabetes, glucose intolerance treated with hypoglycemic agent, history of GDM, history of stillbirth, recurrent miscarriage, history of macrosomia, parity >3, Cushing syndrome, congenital adrenal hyperplasia, hypothyroidism | No | ≥2 of the 100-g OGTT glucose levels exceeded: fasting,
>5.3 mmol/l (>95 mg/dl); 1 h, >10.0 mmol/l (>180 mg/dl);
2 h > 8.6 mmol/l (>155 mg/dl); and 3 h, >7.8 mmol/l
(>140 mg/dl) | Not reported | Long agonist and antagonist protocols | Not reported | IVF/ICSI | Fresh | Not reported | Progesterone | Yes/yes |
|
| Retrospective cross-sectional/October 1999–November 2004 | 26/52 | Yes (by maternal age and the number of fetus) | Control group was selected from the institutional registry/pregnancies resolved before Week 26, diabetes mellitus, systemic chronic arterial hypertension, nephropathies, heart disease and diseases of collagen | Unclear | ≥2 altered values of the glucose tolerance curve of 180 min and by sieve of 50 g of glucose (>180 mg/dl/h). | rFSH (300–450 IU) | Leuprolide/long | ≥3 follicles ≥18 mm and E2 ≥ 500 pg/ml | IVF | Fresh | Day 3 | Progesterone vag. or I.M. gel and oral estradiol | Yes/no |
|
| Retrospective cross-sectional/13-year period | 467/ | No | ART and delivery at the university | Unclear | Not reported | rFSH | Cetrorelix or Decapeptyl (long) | ≥3 follicles ≥17 mm with corresponding E2 serum levels | IVF/ICSI | Fresh/frozen | Not reported | Transdermal estradiol with transvaginal progesterone | Yes/no |
|
| Prospective cross-sectional/June 2009–September 2010 | 76/1013 | No | Aged ≥18 years at 11–14 weeks of gestation/Type 1 diabetes mellitus or were receiving chemotherapy or psychotropic drugs. | Yes | 75 g OGTT after 8–10 h of overnight fasting at 26–28 weeks’
gestation. | Not reported | Not reported | Not reported | Undefined | Undefined | Not reported | Not reported | Yes/yes |
|
| Prospective cross-sectional/February 2004–October 2006 | 358/304 | Yes (parity, age, height, weight, ethnic origin, smoking and no history of infertility) | Male cause of infertility/chronic medical disorders, OHSS, female causes of infertility | Unclear | Not reported | rFSH (225 IU) | Decapeptyl (long) | ≥3 follicles reached 17 mm | ICSI | Fresh | Day 2 | Progesterone vag | Yes/no |
|
| Prospective cross -sectional/January 2000–December 2001 | 634/ | No | 11–13 + 6 weeks of gestation/pregnancies conceived by IUI, those with fetal aneuploidies or major defects | Unclear | Fasting plasma glucose level is at least 6 mmol/l or the plasma glucose level 2 h after the oral administration of 75 g glucose is ≥7.8 mmol/l | Not reported | Not reported | Not reported | IVF | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/January 2013–January 2014 | 1596/112 813 | No | A live or stillborn infant weighing ≥500 g at ≥20 weeks’ gestation/women ≤18 years or with missing maternal age, those with multiple gestations, elective terminations or ectopic or molar pregnancies, and if another form of ART was used | Yes | No: | Not reported | Not reported | Not reported | IVF/ICSI | Fresh/frozen | Not reported | Not reported | Yes/yes |
|
| Prospective cross -sectional/August 1996–March 2004 | 261/443 | No | Pregnancies from infertile couples during the study period | Unclear | Not reported | uhMG or rFSH | Triptorelin acetate/long or Ganirelix | Not reported | IVF/ICSI | Fresh/frozen | Day 2 | Both estradiol valerate and vaginal micronized progesterone | Yes/no |
|
| Prospective cross -sectional/June 2006–December 2008 | 509/587 | No | 6–12 weeks of gestation demonstrating one gestational sac with a fetal heart pulse | Yes | No: | Not reported | Not reported | Not reported | IVF/ICSI | Fresh/frozen | Not reported | Not reported | Yes/yes |
|
| Prospective cross -sectional/June 2006–December 2008 | 504/554 | No | 6–12 weeks of gestation | Yes | No: | Not reported | Not reported | Not reported | Undefined | Undefined | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional/January 1991–December 2013 | 229/7929 | No | Women aged at least 40 years/conceived following oocyte donation, were surrogate mothers, or if they had multifetal pregnancies; aged >45 years | Yes | OGTT | Not reported | Not reported | Not reported | IVF/ICSI | Undefined | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional/January 1993–March 1999 | 69/345 | Yes (maternal age, parity, year of birth, mother’s residence, number of children at birth) | Pregnancies ending in birth/ | Unclear | Not reported | hMG | Buserelin long | ≥3 mature follicles ≥18 mm | IVF/ICSI | Undefined | Day 2 | Progesterone vag | Yes/no |
|
| Prospective cross -sectional/ART: August 1998–August
2000 | 2687/7938 | No | Pregnancies, conceived after an ICSI procedure and the transfer of fresh embryos before the 16th week of gestation. Control cohort was taken from the Congenital Malformation Monitoring-Centre Saxony-Anhalt/those who could not be contacted after inclusion, congenital malformation | Yes | No: | Not reported | Not reported | Not reported | ICSI | Fresh | Not reported | Not reported | Yes/yes |
|
| Prospective cross -sectional/June 1996–December 1999 | 87/85 | Yes (socioeconomic status, gender and birth date) | Singletons conceived by ICSI. Regular preschools and primary
schools with zip codes that indicated social class distributions similar to the
ICSI cohort assisted in the recruitment of naturally conceived
singletons/ | Unclear | No: | Not reported | Not reported | Not reported | ICSI | Fresh | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional | 153/580 | Yes (sex of the child, year of birth, area, maternal age, parity, social class and fetal plurality) | All IVF live births and stillbirths after completion of week 22 of gestation or with a birth weight of ≥500 g derived from registers at the IVF outpatient clinic in the University Hospital and the Infertility Clinic of the Family Federation of Finland/not reported | Yes | Altered glucose metabolism requiring dietary or insulin treatment.
GDM was detected by a 2 h OGTT | hMG | Buserelin or Nafarelin long | Not reported | IVF/ICSI | Fresh | Day 2 | Progesterone or chorionic gonadotropin for 14 days | Yes/yes |
|
| Prospective cross-sectional/not reported | 34/74 | Yes (maternal age, race, ethnicity and fetal sex) | All pregnancies at late first trimester at the time of chorionic villus sampling (CVS) and followed until delivery. | Unclear | No: | Not reported | Not reported | Not reported | Undefined | Fresh/frozen | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional/July 2004–December 2010 | 10 149/ | No | All live births of ≥22 weeks’ gestation and ≥350 g birth weight to Massachusetts resident women | Yes | No: | Not reported | A range of protocols were used (aromatase inhibitors, minimal stimulation, agonist, agonist flare, antagonist) | Not reported | IVF/ICSI | Fresh/frozen | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional/January 2007–December 2011 | 464/1171 | No | All women with either spontaneous or IVF singleton pregnancies
followed at the outpatient clinics of the hospital during study
period/ | Yes | No: | Not reported | Not reported | Not reported | IVF/ICSI | Fresh | Day 3 | Not reported | Yes/no |
|
| Retrospective cross-sectional/1989–1994 | 169/496 | Yes (maternal age, gestational age and parity) | Pregnancies that led to a live birth (≥25 weeks’ gestation or ≥500 g birth weight) | Unclear | Abnormal fasting blood glucose level or abnormal OGTT result between 24 and 28 weeksof gestation/sequential pregnancies | Not reported | Not reported | Not reported | Undefined | Undefined | Not reported | Not reported | Yes/yes |
|
| Prospective cross -sectional/January 2011- March | 2993/88 873 | No | All live births of ≥22 weeks’ gestation | Yes | OGTT with 75 g sugar, diagnostic criteria: blood glucose values of (i) ≥92 mg/dl in a fasted state; (ii) ≥180 mg/dl after 1 h; or (iii) ≥153 mg/dL after 2 h | Not reported | Not reported | Not reported | IVF/ICSI | Fresh/frozen | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional/1991–1996 | 163/322 | Yes (maternal age, gestational age and parity) | Gestational age of at least 24 completed weeks and/or children with >499 g birth weight | Yes | No: | Not reported | Not reported | Not reported | Undefined | Undefined | Not reported | Not reported | Yes/yes |
|
| Prospective cross -sectional/March 2013–February 2016 | 1260/2480 | No | Women who provided informed consent, belonged to singleton pregnancies, participated in the follow-up process and had a complete case report form/deliveries of women <15 years and >60 years, twin, triplet, and quadruplet) pregnancies, egg donation | Unclear | Not reported | Not reported | Not reported | Not reported | IVF/ICSI | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/1983–1993 | 260/260 | Yes (maternal age, parity, ethnic origin, location and date of delivery) | Pregnancies leading to live births (>25 weeks’ gestation or > 500 g birth weight) | Yes | No: | CC + hMG or hMG alone | GnRH analogue (long luteal or follicular) | Leading follicle reached 17–20 mm and serum E2 levels >500 pg/ml | IVF | Fresh/frozen | Not reported | Progesterone I.M. | Yes/yes |
|
| Retrospective cross-sectional/2002–2006 | 20 236/ | No | Data from 16 IVF clinics were cross-linked with the Swedish Medical Birth Registry and compared with all children born after spontaneous conception during the same time period | Yes | No: | rFSH or hMG | Agonist or antagonist protocols | Not reported | IVF/ICSI | Fresh/frozen | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional/1997–1998 | 1400/ | Yes (birth month and year, maternal age, parity, race/ethnicity) | Restriction to singletons AND exclusion if: maternal age <20, education <high school, mother not married, public/no health insurance for prenatal care, public/no health insurance for labour and delivery; no or inadequate prenatal care or third trimester initiation of prenatal care, and data on race/ethnicity missing | Unclear | Not reported | Not reported | Not reported | Not reported | IVF/ICSI | Fresh/frozen | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/January 1999–December 2005 | 176/185 | No | Data collected from all pregnancies that were conceived in the study period/Hereditary disease, children of alcoholic mothers, drug addicts and children of mothers who have used drugs with potential teratogenic effect during pregnancy | Unclear | Not reported | Not reported | Not reported | Not reported | IVF/ICSI | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/1988–2006 | 1294/171 513 | No | All women who conceived and delivered singletons at the Soroka University Medical Center in the study period | Unclear | Not reported | Not reported | Not reported | Not reported | IVF | Undefined | Not reported | Not reported | Yes/no |
|
| Prospective cross-sectional/January 2006–January 2010 | 634/634 | Yes (maternal age, parity, education, and BMI) | All pregnancies with duration of >26 weeks/pregnancies resulting from an oocyte donation, cryopreserved cycles or conceived as twin but continued as singleton | Yes | If at least two values of plasma glucose concentrations are ≥5.28, 10.0, 8.61 or 7.78 mmol/l for fasting, 1-, 2- and 3-h post-glucose load glucose values, after performing a 100 g OGTT (American Diabetes Association, WHO, 1999) | rFSH or hMG | GnRH agonist long | When at least of half of the dominant follicles reached 18 mm in average diameter | IVF/ICSI | Fresh | Day 2 or 3 | Micronized oral/vaginal progesterone 600 mg per day or muscular progesterone 250 mg on every second day | Yes/yes |
|
| Retrospective cross-sectional/2002–2006 | 89/849 | No | Elderly primiparous women (aged ≥35 years)/ | No | A 75-g, 2-h OGTT | Not reported | Not reported | Not reported | IVF/ICSI | Fresh | Not reported | Not reported | Yes/yes |
|
| Retrospective cross-sectional/2004–2014 | 336/308 | Yes (maternal age and parity) | Pregnancies who delivered >22 weeks of gestation/history of preterm birth, gestational hypertensive disorders or placental pathologies in the previous pregnancy, oocyte donation, frozen/thawed ET and major fetal anomalies | Unclear | OGTT of 75 g ≥92 (fasting), ≥180 (1 h) and ≥153 mg/dl (2 h) | Not reported | Not reported | Not reported | IVF/ICSI | Fresh | Not reported | Not reported | Yes/yes |
|
| Prospective cross-sectional/2006–2009 | 283/283 | Yes (ethnic origin, maternal age, gravidity, smoking, BMI, weight gain in pregnancy, site and time of delivery) | Primiparous women ≥35 years of age with a birth weight at least 500 g | Unclear | Not reported | rFSH or hMG | GnRH agonist long | ≥2 follicles reached 16–17 mm in diameter | Undefined | Fresh | Day 3–5 | Progesterone vag gel or capsule | Yes/no |
|
| Retrospective cross-sectional/2004–2010 | 223/460 | No | Only pregnancies that were treated, followed-up and delivered at the Infertility and Assisted Reproduction Unit, Hospital Clinic | Unclear | Not reported | FSH | GnRH agonist | Not reported | IVF/ICSI | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/January 1988–June 1994 | 140/140 | Yes (parity, maternal age, height, weight, no fertility history) | Singleton pregnancies of >20 weeks’ gestation/early pregnancy loss (<20w), embryo reduction, women referred later than 20w’ gestation due to complications | Unclear | Not reported | Not reported | Not reported | Not reported | IVF | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/January 2007–December 2009 | 12 105/ | No | Singleton births during the study period/records that did not state ART status or gestational age | Unclear | Not reported | Not reported | Not reported | Not reported | IVF/ICSI | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/October 2010–October 2012 | 94/164 | No | Newborns admitted to the hospital after delivery | Unclear | Not reported | Not reported | Not reported | Not reported | IVF/ICSI | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/January 2015–January 2018 | 1663/ | Yesv (maternal age, BMI, parity and gravidity) | Deliveries at ≥24 weeks of gestation/uterine malformation, adenomyosis, uterine myoma, submucous myoma, obesity or low weight, severe intrauterine adhesions, chronic hypertension, and diabetes | Yes | 2-h 75 g OGTT between 24 and 28 weeks of gestation, if ≥1 of the three plasma glucose concentrations equalled or exceeded the following values: fasting glucose 5.1 mmol/L, 1-h level 10.0 mmol/L and 2-h level 8.5 mmol/L | Not reported | Not reported | Not reported | IVF/ICSI | Frozen | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/January 1995–February 2002 | 185/185 | Yes (maternal age, parity, gravidity and previous obstetric outcome) | Deliveries at the Department of Obstetrics and Gynecology, University of Szeged in the study period | Unclear | Not reported | Not reported | Not reported | Not reported | Undefined | Undefined | Not reported | Not reported | Yes/no |
|
| Retrospective cross-sectional/2006–2014 | 1659/ | Yes (maternal age and birth year) | Pregnancies conceived during the study period | Unclear | Not reported | Not reported | Not reported | Not reported | IVF/ICSI | Undefined | Not reported | Not reported | Yes/no |
GDM: gestational diabetes mellitus; OGTT: oral glucose tolerance test; rFSH: recombinant FSH, CC: clomiphene citrate; E2: estradiol, CC; Clomiphene citrate, ACOG: SC: spontaneous conception, ET: embryo transfer, PCOS: polycystic ovary syndrome, PN: pronuclei, WHO: World Health Organization, OHSS: ovarian hyperstimulation syndrome
Figure 2Gestational diabetes mellitus after ART versus after spontaneous conception in matched and unmatched studies. RR: risk ratio.
Figure 3Gestational diabetes mellitus after ART versus after spontaneous conception according to type of embryo transfer. ET: embryo transfer.
Figure 4Gestational diabetes mellitus after ART versus after spontaneous conception according to method of fertilization.
Figure 5Gestational diabetes mellitus after ART versus after spontaneous conception in studies including patients with PCOS or not, or whether this information was unclear. PCOS: polycystic ovary syndrome